Cerebral Inc., the telehealth mental health company, may be headed toward a Cerebral CEO lawsuit involving its former co-founder and CEO, Kyle Robertson. Robertson stepped down in May, with Chief Medical Officer Dr. David Mou taking over as CEO. The circumstances of his departure have now become a focal point in what could develop into a legal battle.
Robertson Requests Access to Internal Records
Recently, Robertson sent a formal letter to Cerebral requesting access to internal documents and records. A copy obtained by Behavioral Health Business (BHB) indicates that Robertson’s purpose is to investigate “possible breaches of fiduciary duty, mismanagement and other violations of law” by the company’s board of directors.
This letter functions as a “books and records” request, often the first step in a Cerebral CEO lawsuit. By seeking these documents, Robertson appears to be laying the groundwork for potential litigation.
Allegations Surround Controlled-Substance Prescriptions
A major point of contention highlighted in Robertson’s letter concerns Cerebral’s controlled-substance prescription policies. The letter claims that while Cerebral initially did not prescribe controlled substances, the board later pushed for aggressive prescribing practices during the COVID-19 pandemic. This change was allegedly driven by the temporary waiver of in-person appointment requirements under the Ryan-Haight Act.
“Cerebral did not initially prescribe controlled substances as a company policy,” the letter reads. “Cerebral’s Directors, however, sought to capitalize on the COVID-19 pandemic… by pushing aggressive prescription practices that would attract and retain clients.”
The Department of Justice and other regulatory bodies have reportedly examined these practices, which Cerebral has consistently defended. These issues may play a central role in any Cerebral CEO lawsuit that unfolds.
Claims of Discrimination
Robertson’s letter also alleges that he was removed from his position as CEO because of his LGBTQ status. Cerebral has denied these claims and reiterated its commitment to diversity and inclusion.
“Kyle’s claims against Cerebral and its board are categorically untrue and baseless in law and in fact,” a spokesperson told BHB. “These claims run contrary to our culture of championing diversity and inclusion and are the antithesis of what we stand for as a company. His dismissal was legitimately executed in the company’s best interests. We will defend ourselves vigorously against these claims.”
Historical Context and Prior Legal Disputes
This development follows a prior legal dispute at Cerebral. Matthew Truebe, a former vice president of product and engineering, filed a lawsuit claiming wrongful termination after raising concerns about prescribing practices and data security. Together, these disputes signal ongoing governance and compliance challenges for the company, highlighting the stakes of a potential Cerebral CEO lawsuit.
Potential Implications
If Robertson’s request for internal documents leads to litigation, the Cerebral CEO lawsuit could have broad implications. Beyond legal ramifications, it could draw attention from regulators, policymakers, investors, and the telehealth community. The case could also impact public perception of Cerebral and raise questions about internal governance and telehealth prescribing practices.
As the company prepares to defend itself, the situation underscores the delicate balance between rapid growth, regulatory compliance, and ethical corporate governance in the mental health telehealth industry. Observers are closely watching how this Cerebral CEO lawsuit unfolds, as it may set precedent for other disputes in the fast-growing telehealth sector.
Ultimately, the Cerebral CEO lawsuit represents more than a conflict between a former executive and his company; it could become a defining moment for the telehealth industry, highlighting the need for clear policies, compliance oversight, and strong corporate governance. Whether Robertson succeeds or not, this legal dispute is likely to be closely followed in the coming months.
